Quick Answer
Karyopharm Therapeutics Inc. reported Diluted EPS of $17.93 per share (loss) for fiscal year 2025.
Karyopharm Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$17.93 | -28.1% |
| 2024 | -$14.00 | +25.5% |
| 2023 | -$18.79 | -830.2% |
| 2022 | -$2.02 | -22.4% |
| 2021 | -$1.65 | +39.3% |
| 2020 | -$2.72 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.82 | +0.8% | +11.6% |
| June 30, 2025 | -$4.32 | -45.5% | -56.0% |
| March 31, 2025 | -$2.77 | +42.9% | +28.1% |
| September 30, 2024 | -$3.85 | -1183.3% | -29.6% |
| June 30, 2024 | -$2.97 | -924.1% | +38.8% |
| March 31, 2024 | -$4.85 | -1516.7% | -1516.7% |
| September 30, 2023 | -$0.30 | +33.3% | -3.4% |
| June 30, 2023 | -$0.29 | +53.2% | +3.3% |
- Karyopharm Therapeutics Inc. showed a decrease of -28.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Karyopharm Therapeutics Inc.’s diluted eps has declined by 559.2% (from $2.72 per share (loss) to $17.93 per share (loss)).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: